EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Time-course of drug-related psychiatric and behavioral treatment-emergent adverse events during brivaracetam treatment in adults with focal-onset seizures

Kimford J Meador, Svetlana Dimova, Dimitrios Bourikas, Sami Elmoufti, Florin Floricel, Cédric Laloyaux, Brian Moseley, Xavier Nondonfaz, Pavel Klein

Epilepsy & Behavior · 2024

DOI: 10.1016/j.yebeh.2024.109844 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsy & Behavior, 2024. Verfasst von Kimford J Meador und 8 weiteren Autor:innen. Beteiligte Einrichtung: Stanford University School of Medicine, Palo Alto, CA, USA. Electronic address: kmeador@stanford.edu. Hauptthemen laut MEDLINE: Anticonvulsants, Pyrrolidinones, Seizures. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: We previously analyzed data from three phase lll trials of adjunctive brivaracetam (BRV) in adults showing that the incidence and prevalence of drug-related central nervous system treatment-emergent adverse events (TEAEs) quickly peaked and decreased over several weeks following BRV treatment initiation. However, that analysis did not assess psychiatric and behavioral side effects which can occur with antiseizure medication (ASM) treatment. Here, we investigate the time-course of psychiatric and behavioral TEAEs by week of BRV treatment and how these TEAEs were managed. METHODS: Data were pooled from three trials (N01252 [NCT00490035]; N01253 [NCT00464269]; N01358 [NCT01261325]) in adult patients (≥16 years of age) with focal-onset seizures receiving BRV adjunctive therapy. This post hoc analysis reports data on the incidence and prevalence of drug-related psychiatric or behavioral TEAEs over time in patients who received BRV doses of 50-200 mg/day (without titration) or placebo (PBO) during the 12-week treatment period. A logistic regression model was used to determine if psychiatric or behavioral comorbid conditions were predictors for drug-related psychiatric or behavioral TEAEs, or BRV discontinuation due to psychiatric or behavioral TEAEs. RESULTS: A total of 803 patients received BRV 50-200 mg/day, and 459 patients received PBO. Drug-related psychiatric or behavioral TEAEs were reported by 11.0 % of patients during adjunctive BRV treatment (PBO: 4.8 %) with onset early after BRV initiation (median time to onset of first drug-related psychiatric or behavioral TEAE: 15 days). Incidence peaked at week 1 and decreased over the first 4 weeks following BRV initiation. Prevalence peaked at week 4 and then remained stable between weeks 5-12. In an analysis excluding patients on concomitant levetiracetam (BRV: n = 744; PBO: n = 422), the incidence of drug-related psychiatric or behavioral TEAEs was similar to the incidence in the overall population. The most common drug-related psychiatric or behavioral TEAEs were irritability, insomnia, depression, and anxiety. Only 2 % of patients discontinued BRV due to psychiatric or behavioral TEAEs (PBO: 1.3 %), while most patients on BRV who reported drug-related psychiatric or behavioral TEAEs did not require a change in dose (84.1 %; PBO: 63.6 %). A history of psychiatric or behavioral comorbid conditions (not ongoing at BRV initiation) was not associated with an increased likelihood of drug-related psychiatric or behavioral TEAEs, or BRV discontinuation due to psychiatric or behavioral TEAEs. Ongoing psychiatric or behavioral comorbid conditions at BRV initiation increased the likelihood of drug-related psychiatric or behavioral TEAEs, but not the likelihood of BRV discontinuation due to psychiatric or behavioral TEAEs. CONCLUSIONS: Drug-related psychiatric and behavioral TEAEs occurred early during BRV treatment, and most patients did not require a change in BRV dose. These data can help guide clinician monitoring and patient expectations after starting BRV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsPyrrolidinonesSeizuresHumansMaleAdultFemaleMiddle AgedMental DisordersTime FactorsYoung AdultDouble-Blind MethodEpilepsies, PartialAgedAdolescent

Stichwörter der Autor:innen

Antiseizure medicationBrivaracetamFocal-onset seizuresPsychiatric and behavioral adverse events

Substanzen

brivaracetamAnticonvulsantsPyrrolidinones

Autor:innen und Institutionen

  • Stanford University School of Medicine, Palo Alto, CA, USA. Electronic address: kmeador@stanford.edu.
  • UCB Pharma, Brussels, Belgium. Electronic address: Svetlana.Dimova@ucb.com.
  • UCB Pharma, Alimos, Greece. Electronic address: Dimitrios.Bourikas@ucb.com.
  • UCB Pharma, Morrisville, NC, USA. Electronic address: Sami.Elmoufti@ucb.com.
  • UCB Pharma, Monheim am Rhein, Germany. Electronic address: Florin.Floricel@ucb.com.
  • UCB Pharma, Brussels, Belgium. Electronic address: Cedric.Laloyaux@ucb.com.

Zitieren

APA

Meador, K. J., Dimova, S., Bourikas, D., Elmoufti, S., Floricel, F., Laloyaux, C., Moseley, B., Nondonfaz, X., & Klein, P. (2024). Time-course of drug-related psychiatric and behavioral treatment-emergent adverse events during brivaracetam treatment in adults with focal-onset seizures. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2024.109844

Vancouver

Meador KJ, Dimova S, Bourikas D, Elmoufti S, Floricel F, Laloyaux C, et al. Time-course of drug-related psychiatric and behavioral treatment-emergent adverse events during brivaracetam treatment in adults with focal-onset seizures. Epilepsy & Behavior. 2024. doi:10.1016/j.yebeh.2024.109844

BibTeX
@article{Meador2024,
  author = {Meador, Kimford J and Dimova, Svetlana and Bourikas, Dimitrios and Elmoufti, Sami and Floricel, Florin and Laloyaux, Cédric and Moseley, Brian and Nondonfaz, Xavier and Klein, Pavel},
  title = {Time-course of drug-related psychiatric and behavioral treatment-emergent adverse events during brivaracetam treatment in adults with focal-onset seizures},
  journal = {Epilepsy & Behavior},
  year = {2024},
  doi = {10.1016/j.yebeh.2024.109844}
}
Kostenlos starten →